Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

Spotlight on Molecular Targeted Therapy

Developmental Therapeutics Program at the NCI: molecular target and drug discovery process

Abstract

As the drug discovery and developmental arm of the National Cancer Institute (NCI), the Developmental Therapeutics Program (DTP) plans, conducts and facilitates development of therapeutic agents for cancer and AIDS. DTP's goal is to turn ‘molecules into medicine for the public health’. Areas of support by DTP are discovery, development and pathways to development for the intramural and the extramural community. The Developmental Therapeutics Program (DTP) operates a repository of synthetic and pure natural products, which are evaluated as potential anticancer agents. The repository derives from a historical database of greater than 600 000 compounds, which have been supplied to DTP from a variety of sources worldwide. The in vitro anti-cancer drug cell line screen established at DTP is unique in several respects. It has changed the NCI emphasis from a compound-oriented drug discovery effort to a disease-panel oriented exercise, emphasized human tumor cells derived from solid tumors, developed a high volume screening method that can adapt to processing of numerous chemical agents or natural source-derived extracts, that has minimized the use of animals, and saved on the amount of material required for the initial screening. The hollow fiber assay created at the DTP has demonstrated the ability to provide quantitative initial indices of in vivo drug efficacy, with minimum expenditures of time and materials and is currently being utilized as the initial in vivo experience for agents found to have reproducible activity in the in vitroanticancer drug screen. Drugs showing activity with unique mechanisms of actions are being further developed for treatment of hematopoietic neoplasms, prominent examples being flavopiridol, UCN-01 and depsipeptide among others.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Sausville EA, Feigal E . Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA Ann Oncol 1999 10: 1287–1291

    Article  CAS  PubMed  Google Scholar 

  2. Sausville E, Shoemaker R . Role of the national cancer institute in acquired immunodeficiency syndrome-related drug discovery J Natl Cancer Inst Monogr 2001 28: 55–57

    Google Scholar 

  3. Hodes L . Selection of molecular fragment features for structure–activity studies in antitumor screening J Chem Inf Comput Sci 1981 21: 132–136

    Article  CAS  PubMed  Google Scholar 

  4. Driscoll JS . The pre-clinical new drug research program of the National Cancer Institute Cancer Treat Rep 1984 68: 63–76

    CAS  PubMed  Google Scholar 

  5. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL . Feasibility of drug screening with panels of human tumor cell lines using a micro culture tetrazolium assay Cancer Res 1988 48: 589–601

    CAS  PubMed  Google Scholar 

  6. Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA . The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets Anticancer Drug Des 1997 12: 533–541

    CAS  PubMed  Google Scholar 

  7. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L . In vivo cultivation of tumor cells in hollow fibers Life Sci 1995 57: 131–141

    Article  CAS  PubMed  Google Scholar 

  8. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA . Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br J Cancer 2001 84: 1424–1431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS . The hollow fiber assay: continued characterization with novel approaches Anticancer Res 2000 20: 903–911

    CAS  PubMed  Google Scholar 

  10. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J Natl Cancer Inst 1989 81: 1088–1092

    Article  CAS  PubMed  Google Scholar 

  11. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T . Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen J Clin Invest 1995 95: 2205–2214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD . An information-intensive approach to the molecular pharmacology of cancer Science 1997 275: 343–349

    Article  CAS  PubMed  Google Scholar 

  13. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN . A gene expression database for the molecular pharmacology of cancer Nat Genet 2000 24: 236–244

    Article  CAS  PubMed  Google Scholar 

  14. Koo HM, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ . Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes Cancer Res 1996 56: 5211–5216

    CAS  PubMed  Google Scholar 

  15. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD, Liu ED . Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia Blood 1994 83: 1603–1611

    CAS  PubMed  Google Scholar 

  16. Schein P, Anderson T . The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs Int J Clin Pharmacol 1973 8: 228–238

    CAS  PubMed  Google Scholar 

  17. Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L . Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis J Clin Invest 1998 102: 1674–1681

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT . Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts Blood 1998 91: 2482–2490

    CAS  PubMed  Google Scholar 

  19. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ . Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells Cancer Res 1996 56: 2973–2978

    CAS  PubMed  Google Scholar 

  20. Arguello F, Alexander M, Sterry J, Yudor G, Smith E, Kalavar N, Greene J, Koss W, Morgan D, Stinson S, Siford T, Alvord W, Labansky R, Sausville E . Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts Blood 1998 91: 2482–2490

    CAS  PubMed  Google Scholar 

  21. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville EA, Grever MR . Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood 1998 92: 3804–3816

    CAS  PubMed  Google Scholar 

  22. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM . Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol Blood 1998 91: 458–465

    CAS  PubMed  Google Scholar 

  23. Kitada S, Zapata JM, Andreeff M, Reed JC . Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down- regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia Blood 2000 96: 393–397

    CAS  PubMed  Google Scholar 

  24. Guedez L, Quintanilla-Martinez L, Lahusen T, Davies T, Singh SS, Barotto N, Vistica D, Raffeld M, Sausville EA, Senderwicz AM . Flavopiridol-induced apoptosis is associated with a decrease in cyclin D1 in mantle lymphoma cell lines Proc 90th Annual Meeting of the American Association of Cancer Research, Philadelphia, PA 1999

    Google Scholar 

  25. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA . Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms J Clin Oncol 1998 16: 2986–2999

    Article  CAS  PubMed  Google Scholar 

  26. Thomas J, Cleary J, Tutsch K, Arzoomanian R, Alberti D, Simon K, Feierabend D, Morgan K, Wilding G . Phase I clinical and pharmokinetic trial of flavopiridol Proc 88th Annual Meeting of the American Association of Cancer Research, San Diego, CA 1997

    Google Scholar 

  27. Shah MA, Kaubisch A, O'Reilly S . A phase IB clinical trial of the sequence dependent combination of paclitaxel (P) and cisplatin (C) with cyclin dependent kinase (CDK) inhibitor flavopiridol in patients with advanced solid tumors Proceedings of AACR 2001 42: 2917a

    Google Scholar 

  28. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM . Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms J Clin Oncol 2001 19: 2319–2333

    Article  CAS  PubMed  Google Scholar 

  29. Wilson WH, Gutierrez M, Stetler-Stevenson M, Drbohlav N, Staudt L, Figg W, Sausville EA, Fowler D, Bishop M, Hegde U . Phase I trial of 7-hydroxystaurosporine (UCN-01) and fludarabine phosphate; in vivo evidence of UCN-01 induced apoptosis in CLL ASH Proc 2000 96: 3268a

    Google Scholar 

  30. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn I, Dawson NA, Grever MR . Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells Blood 1999 94: 1401–1408

    CAS  PubMed  Google Scholar 

  31. Bates SE, Sandor V, Bakke S . A phase I study of FR901228 (Depsipeptide), a histone deacetylase inhibitor ASCO Proc 1999 18: 693a

    Google Scholar 

Download references

Acknowledgements

We are indebted to Dr Richard Messmann for the figures.

Author information

Authors and Affiliations

Authors

Additional information

This article is a ‘United States Government Work’ paper as defined by the US Copyright Act

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monga, M., Sausville, E. Developmental Therapeutics Program at the NCI: molecular target and drug discovery process. Leukemia 16, 520–526 (2002). https://doi.org/10.1038/sj.leu.2402464

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402464

Keywords

This article is cited by

Search

Quick links